This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix To Present SUMAVEL(R) DosePro(TM) Phase 4 Results At American Academy Of Neurology

SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL ® DosePro™ (sumatriptan injection) Needle-free Delivery System will be presented in two posters at the 63 rd Annual Meeting of the American Academy of Neurology (AAN), to be held April 9 – 16, 2011 at the Hawaii Convention Center, Honolulu, HI. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com .

The Phase 4 open-label, multicenter U.S. study evaluated overall satisfaction, confidence and preference for SUMAVEL DosePro in treating multiple migraine attacks in more than 200 adult patients diagnosed with migraine and currently taking triptan therapy. Efficacy, including onset and sustained duration of pain relief/freedom from pain, and tolerability of therapy with SUMAVEL DosePro were also measured.

Title: Improved Treatment Satisfaction and Confidence Among Current Triptan Users Trying SUMAVEL® DosePro™ (needle-free subcutaneous sumatriptan) for Up to 4 Migraine Attacks
Authors: Cady R, Aurora SK, Brandes JL, Rothrock J, Myers JA, Fox AW, Farr SJ
Date & Time: Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number: NO P05.275
   
   
Title: Multiple-Attack Efficacy and Tolerability of SUMAVEL ® DosePro™ (needle-free subcutaneous sumatriptan) Among Current Triptan Users
Authors: Brandes JL, Rothrock J, Cady R, Aurora SK, Myers JA, Fox AW, Farr SJ
Date & Time: Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number: NO P05.283

Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010 for the acute treatment of migraine and cluster headache.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs